급성 반복성 발작 시장 기회, 성장 촉진요인, 산업 동향 분석 및 예측(2024-2032년)

The Global Acute Repetitive Seizures Market reached USD 2.7 billion in 2023 and is projected to experience 12.4% CAGR over 2024-2032. This growth is primarily attributed to the rising incidence of epilepsy and innovations in emergency treatment options. Recent advancements in intranasal formulations have notably transformed the market landscape. New therapies that offer rapid, non-invasive administration are becoming increasingly popular, especially in home care settings where accessibility is paramount for patients and their caregivers. The ease of use and quick action of these intranasal therapies have accelerated their adoption, allowing for immediate intervention without professional medical supervision.

Acute repetitive seizures, also referred to as seizure clusters, occur when a series of seizures transpire within a short period, typically 24 to 48 hours. These episodes can escalate into status epilepticus, a potentially life-threatening condition. For many individuals living with epilepsy, especially those who struggle to control their seizures, addressing ARS is critical. This growing need for effective treatment options is driving the market forward.

In terms of product classification, the market includes a range of solutions, each addressing the specific needs of patients. One of the leading segments is characterized by its user-friendly and non-invasive delivery method, which facilitates quick absorption and rapid seizure control-an essential factor during emergencies. The approval of certain treatments by regulatory bodies has further enhanced their acceptance and use within the healthcare community. When considering distribution channels, the market is segmented into hospital pharmacies, retail pharmacies, and online platforms.

Hospital pharmacies are anticipated to see significant growth, with a projected CAGR of 12.2%. This increase is driven by the frequent hospital admissions related to acute repetitive seizures, leading to heightened demand for effective seizure management medications. Additionally, these pharmacies often work closely with specialists to create effective protocols for seizure treatment, thus improving both the accessibility and efficacy of the medications. North America acute repetitive seizures market reached USD 1.1 billion in 2023 and is expected to grow at an impressive CAGR of 12.3%.

The region's high prevalence of epilepsy significantly influences the demand for effective treatment options, while a well-established healthcare system supports timely diagnoses and interventions. Moreover, increased public awareness and education surrounding seizure disorders have resulted in more frequent diagnoses, further driving market growth. Overall, the acute repetitive seizures market is poised for significant advancements as the need for effective, accessible treatment options continues to rise.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of epilepsy and seizure disorders
    • 3.2.1.2 Development of novel rescue medications
    • 3.2.1.3 Advances in non-invasive drug delivery systems
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Limited awareness and diagnosis
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 USL-261
• 5.3 Diastat Rectal Gel (DRG)
• 5.4 NRL-1
• 5.5 Other products

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Intranasal
• 6.3 Rectal
• 6.4 Oral
• 6.5 Other routes of administration

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacies
• 7.3 Retail pharmacies
• 7.4 Online pharmacies

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 AdvaCare Pharma Limited
• 9.2 Aquestive Therapeutics
• 9.3 Bausch Health Companies
• 9.4 Lupin Limited
• 9.5 Neuracle Lifesciences
• 9.6 Neurelis
• 9.7 Pfizer
• 9.8 Sanofi
• 9.9 Takeda Pharmaceutical Company Limited
• 9.10 Teva Pharmaceutical Industries
• 9.11 UCB S.A.
• 9.12 Veriton Pharma